Genflow Biosciences PLC Announces Total Voting Rights
-
Auger-Aliassime ends Vacherot run to reach Paris Masters semis
-
Australia captain Wilson denies Wallabies use 'dangerous' breakdown tactics
-
'Populists can be beaten': Dutch centrist Jetten claims election win
-
China's suspension of rare earth controls applies to EU: official
-
Italy complains about strong euro, urges ECB to cut rates
-
Louvre to get anti-ramming barriers by year end: minister
-
Wall Street bounces on Amazon, Apple earnings
-
AI giants turn to massive debt to finance tech race
-
Japan PM says raised 'serious concerns' with Xi on South China Sea, Xinjiang
-
Shein set to open first physical store in Paris
-
Turkish court jails 11 for life over deadly hotel fire
-
Hazlewood stars as Australia ease past India to win 2nd T20
-
Stocks extend losses tracking AI, Fed and trade
-
Arteta concerned for players' welfare in Arsenal fixture pile-up
-
From adored prince to royal outcast, Andrew's protracted downfall
-
Maresca backs 'stupid' Delap to come good for Chelsea
-
Pakistan, Afghanistan extend ceasefire, to hold another round of peace talks
-
Sudan's RSF says arrests fighters accused of abuses in El-Fasher
-
Key dates in the fall of Britain's former prince Andrew
-
Cricket falls silent across Australia after teenager killed by ball
-
Vinicius Junior in the clear over Clasico outburst
-
UK welcomes king's move to strip Andrew of royal titles
-
Liverpool must snap losing 'habit', says under-fire Slot
-
Bencic out of Hong Kong last eight as tennis injury list mounts
-
Xi invites Canada PM to China in first meet in 8 years
-
Chinese defence minister seeks 'trust' with US but cautions over Taiwan
-
India's Rodrigues beat anxiety and tears to become World Cup star
-
Asia markets diverge on heels of Apple, Amazon earnings
-
China, Canada leaders hold first formal talks since 2017
-
Trump stirs global tensions with surprise nuclear test order
-
Nvidia to supply 260,000 cutting-edge chips to South Korea
-
Camels replace cows as Kenya battles drought
-
Endangered across west Africa, leopards thrive in I.Coast reserve
-
Risky gold rush drives young into Ivory Coast nature park
-
Deadly roads block mothers from care in jihadist-hit Nigeria
-
Pillaged I.Coast nature reserve on the mend after crisis decade
-
India savours 'greatest day' after Women's World Cup heroics
-
Why emboldened Kim had little need for photo-op with Trump
-
In the black: the business of mourning Thailand's queen mother
-
Tributes as death of Australian teenager touches cricket world
-
Nearly 50 dead after Hurricane Melissa thrashes Caribbean
-
Jackson throws four TD passes as Ravens rout Dolphins
-
NBA champs Thunder roll past Wizards, Bucks and Spurs win
-
UK's Andrew in freefall, stripped of queen's protection
-
Real Madrid and Barcelona aim to shake off Clasico consequences
-
Ambitious Paris FC making steady progress after landing in big time
-
Rebuilt Leverkusen hope to reignite Bundesliga rivalry at Bayern
-
Xi primed to meet Japan, Canada leaders after Trump summit
-
Australia coach Schmidt pleads for Edmed patience ahead of England clash
-
Liverpool feel pressure to end 'crisis' run, Man City test Bournemouth limits
NYSE - LSE
| SCS | -0.11% | 15.942 | $ | |
| CMSC | -0.12% | 24.03 | $ | |
| AZN | -0.22% | 82.16 | $ | |
| CMSD | -0.25% | 24.3 | $ | |
| RIO | -0.21% | 72.05 | $ | |
| RELX | -0.72% | 44.055 | $ | |
| GSK | 0.17% | 47.02 | $ | |
| RBGPF | 0% | 76 | $ | |
| BCE | -0.61% | 22.97 | $ | |
| RYCEF | 0.58% | 15.45 | $ | |
| JRI | 0.07% | 13.88 | $ | |
| VOD | 0.37% | 12.015 | $ | |
| NGG | -1.33% | 75.05 | $ | |
| BTI | -0.17% | 51.195 | $ | |
| BCC | 1.77% | 70.43 | $ | |
| BP | -0.01% | 34.765 | $ |
Genflow Biosciences PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.
The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
-Ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
J.Oliveira--AMWN
